Alnylam Pharmaceuticals, Inc. ALNY

Revenue Intelligence Report • 13 quarters of SEC filing data • Updated 2026-03-15

Revenue is driven primarily by SG&A spending, which yields a positive long-run impact of $0.05 of revenue per $1 spent, while R&D spending has a negative long-run impact of $-0.51 per $1. The modeling is linear, with an 11.8% MAPE and a holdout test predicting $31M for the latest quarter versus actual $30M (−4.0% error). The FY forecast calls for $144M in revenue, up 34.8% year over year, signaling meaningful top-line momentum. Outlook suggests growth hinges on SG&A leverage with R&D remaining a drag on long-run revenue, so investors should monitor spend mix and efficiency to gauge sustainability.

Investment Thesis

At 11.8% MAPE, the model captures Alnylam Pharmaceuticals, Inc.'s broad revenue trajectory, though quarterly variability suggests sensitivity to external factors. Each $1 of SG&A spending generates $0.06 in revenue, reflecting strong commercial efficiency.

Next FY Revenue
$143.9M
+34.8% YoY
R&D Multiplier
$-0.51 per $1
SG&A Multiplier
$0.06 per $1
Model Accuracy
11.8% MAPE
Holdout validation: The model predicted $31M vs the actual $30M — an error of 4.0%.
⚠ Model limitation: This company shows negative spending multipliers, meaning increases in spending have not directly translated into revenue growth. This typically occurs with commodity-driven companies or hypergrowth companies.

Revenue Forecast

ALNY Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q3 2018 $31M $30M $25M – $37M +95.2% ✓ In range
Q4 2018 $46M $38M – $54M +166.9%
Q1 2019 $18M $8.4M – $28M -51.9%
Q2 2019 $36M $25M – $48M +65.4%
Q3 2019 $44M $31M – $57M +46.6%

How Spending Drives Revenue

ALNY Spending Timing
Reading this chart: Each line shows the cumulative revenue generated per $1 spent over subsequent quarters. The effect builds over 4-5 quarters as investments mature.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch